CURE ADOA FOUNDATION
The road to treatment
We regularly contact various researchers and pharmaceutical companies, nationally and internationally, about the treatment and cure of ADOA(-plus). Below you will find the reports of these conversations and interviews. Thanks to a number of fanatical volunteers led by Peter Makai.
#31: From mitochondrial transplantation to hearing problems
Promising research into ADOA(-plus) and mitochondria In previous posts on the road to treatment, we have mainly highlighted research in the United States. But also in
#30: ASHA Therapeutics' Approach to Slowing and Partially Reversing ADOA
New Developments in ADOA Research: ASHA Therapeutics' Approach to Slow and Partially Reverse ADOA by Peter Makai End of April
#29: A breakthrough in retinal cell therapy
Restoring Vision: A Breakthrough in Retinal Cell Therapy Autosomal Dominant Optic Atrophy (ADOA) is a genetic disorder that primarily affects the optic nerves. The optic nerves are
#28: Interview with Christina Eckmann-Hansen about the impact of ADOA
The Impact of ADOA – Interview with Christina Eckmann-Hansen In October we spoke with Christina Eckmann-Hansen, an optometrist who did a PhD research on ADOA at
The road to treatment 27
New Developments in Optic Nerve Regeneration – Interview with Petr Baranov We had an interview with Dr. Petr Baranov, a researcher at
The road to treatment 26
PYC: first patient to receive ADOA medication in October 2024 At the end of September we had a joint meeting with PYC and the Autosomal Dominant Optic Atrophy Association,
The road to treatment 25
How do clinical trials work at ADOA? Right now, several companies are about to start clinical trials (PYC, Stoke, etc.). These are
The road to treatment 24
Taking stock of Idebenone By Peter Makai PhD and Christina Barckhausen PhD Idebenone is a licensed drug for the disease Leber hereditary optic neuropathy
The road to treatment 23
The Road to Treatment 23 Interview with Tom Schwarz from Harvard We contacted Thomas Schwarz, who is a Professor of Neurobiology at Harvard Medical
The road to treatment 22
The road to treatment 22 At the end of February we had a consultation with Phosphoenix, a Dutch company that is developing a
The road to treatment 21
Dr. Astrid Plomp was present on the Anniversary Day on November 18, 2023 and spoke about clinical genetics. What does a clinical geneticist do? The first
The road to treatment 20
The road to treatment 20 Fatigue – Ruth van Nispen and Manon Veldman Ruth van Nispen and Manon Veldman were present at the ADOA day
